Fig. 6: PPARγ is expressed and functional in mouse ILC2s.

a Expression of Pparg assessed by qPCR analysis in freshly-sorted ILC subsets from the lung of C57BL6 mice (n = 3). b Representative example of flow cytometry analysis of mouse ILC2-derived IL-13 upon T0070907 treatment in vitro. c Frequencies of IL-13 and IL-5 positive ILC2s untreated (open red circle) and after T0070907 treatment (open blue circle) (n = 4; *P = 0.0101, **P = 0.0015). d Expression of Pparg assessed by qPCR analysis in freshly-sorted ILC2s from the lung of IL-33/IL-25-treated Pparg^fl/flId2CreER^T2 positive (open blue circle) or CreER^T2 negative mice (open red circle) (n = 10, **P = 0.0098). e Quantification of IL-13 and IL-5 assessed by Legendplex analysis in cell culture supernatants of murine ILC2s upon stimulation with IL-33 and IL-25 in vitro (Pparg^fl/flId2CreER^T2 positive (open blue circle) or CreER^T2 negative mice (open red circle)) (Pparg^fl/flId2CreER^T2 negative n = 11, Pparg^fl/flId2CreER^T2 positive n = 14; IL-13 **P = 0.0086, IL-5 **P = 0.0035). f Location of motives similar to the PPARγ-RXRα binding motif (top) in the promoter region of IL-5 and IL-13 (mouse genome). The motives with the lowest raw p-value found by the FIMO tool (blue) or the highest score found by the HOMER software (orange) are shown. The Integrative Genomics Viewer (IGV, v2.8.0) was used to represent the location of these motifs within the IL-5 and IL-13 promoters⁸⁴. See Supplementary Data 2 for complete motif search results. Each symbol represents one individual mouse. Data are shown as mean ± SEM and were analyzed by Wilcoxon (d) or two-way (c, e) ANOVA tests. Source data are provided as a Source data file.